27851-29-2

Usage

Uses

Used in Pharmaceutical Industry:
1,2,3,4-TETRABENZYL-BETA-D-GLUCOPYRANOSE is used as an intermediate in the synthesis of complex organic molecules, particularly in the pharmaceutical industry. Its unique structure allows for the creation of novel drug candidates with potential therapeutic applications.
Used in Organic Synthesis:
1,2,3,4-TETRABENZYL-BETA-D-GLUCOPYRANOSE is used as a key intermediate in organic synthesis for the preparation of various biologically active compounds. Its benzyl-protected hydroxyl groups provide a versatile platform for further functionalization and modification, enabling the development of new chemical entities with potential applications in medicine, agrochemicals, and other fields.
Used in the Synthesis of Isomaltose-13C (I821252):
1,2,3,4-TETRABENZYL-BETA-D-GLUCOPYRANOSE is used as an intermediate in the synthesis of Isomaltose-13C (I821252), a labeled isomaltose compound. 1,2,3,4-TETRABENZYL-BETA-D-GLUCOPYRANOSE is one of the main products of the transformation of maltose into prebiotic isomaltooligosaccharides by novel α-glucosidase from Xanthophillomyces dendrorhous. The synthesis of such labeled compounds is essential for research and development in various scientific fields, including biochemistry, molecular biology, and pharmaceuticals.

InChI:InChI=1/C34H36O6/c35-21-30-31(36-22-26-13-5-1-6-14-26)32(37-23-27-15-7-2-8-16-27)33(38-24-28-17-9-3-10-18-28)34(40-30)39-25-29-19-11-4-12-20-29/h1-20,30-35H,21-25H2/t30?,31-,32+,33+,34-/m1/s1

Upstream product

• 183953-29-9 benzyl 2,3-di-O-benzyl-4,6-O-benzylidene-β-D-glucopyranoside 
• 291527-97-4 benzyl 6-O-tert-butyldiphenylsilyl-2,3,4-tri-O-benzyl-β-D-glucopyranoside 
• 27851-28-1 (2R,3R,4S,5R,6R)-2,3,4,5-tetrakis(benzyloxy)-6-((trityloxy)methyl)tetrahydro-2H-pyran 
• 953812-26-5 (3R,4S,5R,6R)-2,3,4,5-tetrakis(benzyloxy)-6-((trityloxy)methyl)tetrahydro-2H-pyran 
• 10343-13-2 benzyl-2,3,4,6-tetra-O-acetyl-β-D-glucopyranoside 
• 83-87-4 D-glucose pentaacetate 
• 572-09-8 2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl bromide 
• 2280-44-6 D-Glucose 
• 50-99-7 D-glucose 
• 203632-36-4 benzyl 6-tert-butyldimethylsilyl-D-glucopyranoside 
• 34246-23-6 benzyl D-glucopyranoside 
• 1423019-40-2 benzyl 2,3,4-tri-O-benzyl-6-tert-butyldimethylsilyl-D-glucopyranoside 
• 100-39-0 benzyl bromide 
• 66966-07-2 α/β‐L‐glucopyranosyl‐1,2,3,4,5‐pentaacetate 

Downstream Products

• 151075-88-6 benzyl 2,3,4-tri-O-benzyl-6-O-trifluoromethanesulfonyl-β-D-glucopyranoside 
• 116525-10-1 benzyl O-(2,3,4,6-tetra-O-benzyl-β-D-glucopyranosyl)-(1->6)-2,3,4-tri-O-benzyl-β-D-glucopyranoside 
• 116525-09-8 benzyl O-(2,3,4,6-tetra-O-benzyl-α-D-glucopyranosyl)-(1->6)-2,3,4-tri-O-benzyl-β-D-glucopyranoside 
• 53929-41-2 C₆₈H₇₀O₁₁ 
• 83866-11-9 2,3,4-tri-O-benzyl-6-O-(2,3,4-tri-O-benzyl-α-L-rhamnopyranosyl)-β-D-glucopyranoside 
• 83866-18-6 benzyl 2,3,4-tri-O-benzyl-6-O-(2,3:5,6-di-O-isopropylidene α-D-mannofuranosyl)-β-D-glucopyranoside 
• 137334-41-9 C₁₁₇H₁₀₄O₃₁ 
• 107855-20-9 benzyl 2,3,4,6-tetra-O-benzyl-β-D-galactopyranosyl-(1->6)-2,3,4-tri-O-benzyl-β-D-glucopyranoside 
• 107855-19-6 benzyl 2,3,4,6-tetra-O-benzyl-α-D-galactopyranosyl-(1->6)-2,3,4-tri-O-benzyl-β-D-glucopyranoside 
• 127138-46-9 benzyl 6-O-(2,3,4-tri-O-acetyl-β-D-xylopyranosyl)-2,3,4-tri-O-benzyl-β-D-glucopyranoside 
• 223545-81-1 benzyl O-(2-azido-3,4,6-tri-O-benzyl-2-deoxy-β-D-glucopyranosyl)-(1->6)-2,3,4-tri-O-benzyl-β-D-glucopyranoside 
• 223545-79-7 benzyl O-(2-azido-3,4,6-tri-O-benzyl-2-deoxy-α-D-glucopyranosyl)-(1->6)-2,3,4-tri-O-benzyl-β-D-glucopyranoside 
• 106837-24-5 benzyl O-(2-azido-3,4,6-tri-O-benzyl-2-deoxy-β-D-mannopyranosyl)-(1->6)-2,3,4-tri-O-benzyl-β-D-glucopyranoside 
• 231284-64-3 C₆₉H₇₁FO₁₂ 

Relevant academic research and scientific papers

Synthesis and conformational analysis of D-gluco-pyranosyl-(6,6′)-D-gluco-pyranuronate, a model compound for the inter-glycan 6,6′-ester linkage

The synthesis of a 6,6′-ester linked disaccharide analog model compound was achieved in five steps from D-glucose and featured a key oxidative esterification transformation. The synthesized D-gluco-pyranosyl-(6,6′)-D-gluco-pyranuronate was characterized in D2O using NMR spectroscopy. Using the experimental data together with molecular dynamics simulations (TIP3P, water), a model of the compound's conformational behavior was established. The effect of the 6,6′-ester linkage on the solution phase structure was compared to that of the previously reported 6,6′-ether linkage in a disaccharide analog. Based on the established models, the ester linkage was found to have a profound effect on the overall shape of the molecule.

INHIBITORS OF MALARIAL AND PLASMODIUM FALCIPARUM HEXOSE TRANSPORTER AND USES THEREOF

Provided are molecules capable of binding to binding pockets of Plasmodium falciparum hexose transporter (PfHT) or analogs thereof and complexes comprising the same. Also provided herein are inhibitors of PfHT, pharmaceutical compositions comprising the i

New class of alkynyl glycoside analogues as tyrosinase inhibitors

A new series of alkynyl glycoside analogues were designed and synthesized from cheap and a commercially available sugar by introduction of various alkynyl and alkyl groups at C-1 and C-6 positions of the sugar ring. The inhibitory abilities of alkynyl gly

Addressing the biochemical foundations of a glucose-based "trojan horse"-strategy to boron neutron capture therapy: From chemical synthesis to in vitro assessment

Boron neutron capture therapy (BNCT) for cancer is on the rise worldwide due to recent developments of in-hospital neutron accelerators which are expected to revolutionize patient treatments. There is an urgent need for improved boron delivery agents, and herein we have focused on studying the biochemical foundations upon which a successful GLUT1-targeting strategy to BNCT could be based. By combining synthesis and molecular modeling with affinity and cytotoxicity studies, we unravel the mechanisms behind the considerable potential of appropriately designed glucoconjugates as boron delivery agents for BNCT. In addition to addressing the biochemical premises of the approach in detail, we report on a hit glucoconjugate which displays good cytocompatibility, aqueous solubility, high transporter affinity, and, crucially, an exceptional boron delivery capacity in the in vitro assessment thereby pointing toward the significant potential embedded in this approach.

ELECTROCHEMICAL METHODS AND COMPOUNDS FOR THE DETECTION OF ENZYMES

Disclosed are compositions and methods for the electrochemical detection of enzymes, such as enzymes that are indicative of disease, disorders, or pathogens, such as viruses, bacteria, and fungi, or other disorders. These methods can be used in point-of- care diagnostic assays for the detection of disease, disorder, or pathogen (e.g., to identify the strain of pathogen infecting a patient in a healthcare setting). The electrochemical methods described herein can also be used to assess the susceptibility of a pathogen to an antipathogen drug. Also provided are probes suitable for use in conjunction with the methods described herein.

A novel selectfluor-mediated regioselective O-benzyl ether acetolysis of perbenzylated monosaccharides

Selectfluor, a source of the super electrophile F+, has replaced conventional reagents that supply F+ for fluorination due to its attractive physical and chemical properties. This study is the first report of using Selectfluor as a d

Electrochemical assay to detect influenza viruses and measure drug susceptibility

An electrochemical assay has been designed to rapidly diagnose influenza viruses. Exposure of a glucose-bearing substrate to influenza viruses or its enzyme, neuraminidase (NA), releases glucose, which was detected amperometrically. Two methods were used

AMPHETAMINE PRODRUGS

The present invention relates to amphetamine prodrugs which provide colonic release of amphetamine.

Design, synthesis and biological evaluation of multivalent glucosides with high affinity as ligands for brain targeting liposomes

The new bifunctional cluster glucosides were designed and synthesized as liposome ligands for preparing novel liposome to achieve the effective delivery of drug formulations to brain by GLUT1. Docetaxel-loaded five liposomes were prepared successfully and tested in the animals. Results from the in vivo distribution study after i.v. administration of these five liposomes and blank-docetaxel indicated that the coupled liposomes Lip-1, Lip-2, Lip-3, Lip-5 exhibited excellent transport ability across the BBB. In particular, they significantly increased the level of docetaxel in brain compared to blank-docetaxel and Lip. Among them, Lip-5 showed higher brain concentration. Both pharmacokinetics and distribution study in mice confirmed that this novel brain targeting drug delivery system was a promising carrier to enhance brain delivery capacity for CNS drugs.

COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS

One aspect of the present invention relates to compounds, compositions and methods for diagnosis and/or treatment of a subject suffering from an amyloidosis-associated pathological condition. In certain embodiments, the imaging and/or therapeutic agents of the instant invention may be administered to a subject for identification and/or treatment of amyloid deposits. A specific imaging method detects amyloid deposits by administering the imaging agent to the subject and detecting the spatial distribution of the agent. Differential accumulation of the agent is indicative of AD or an amyIoidosis-associated pathological condition and can be monitored by using a PET or SPECT camera.